Arcellx – Leveling Up By Challenging Assumptions

Published on : Published by : BioBuzz Media

One year after Rami Elghandour joined Arcellx, Inc., a cell therapy company based in Gaithersburg, MD, and Foster City, CA, as the company’s new chairman and CEO, he took the company public, netting $128 million and funding operations into the second half of 2023. If the IPO had occurred in 2020 or 2021, it may not have been all that surprising. Instead, Arcellx completed its IPO in February 2022, a time when key biotech stock indexes continued a precipitous drop that began in the second half of 2021, causing many biopharma companies to delay IPO plans indefinitely.
It wasn’t Elghandour’s first rodeo. In 2011, he led a $58 million Series B financing round for Nevro Corp., a Silicon Valley-based neuromodulation medical device company, representing Johnson & Johnson Development Corporation (JJDC), where he worked as principal, venture investments. In 2012 Elghandour departed JJDC for Nevro, and was promoted to president in 2014, and CEO in 2016. Nevro went public in 2014, completing its IPO with net proceeds of approximately $131 million. The experience of Nevro’s pre-COVID IPO road show, which Elghandour describes as “brutal, but memorable,” was a learning experience. The biggest difference between Nevro’s IPO in 2014 and Arcellx’s IPO…

Rethinking Your Company’s Visual Brand Part 2 – Investing in Better Imagery

Published on : Published by : Sarah Ellinwood

Last week, we delved into why visual branding is important in helping your life science company stand out from the crowd to attract audiences such as investors and potential talent. We also provided a few tips on how to start thinking about your company’s science and approach differently so that you could create a style that is all your own. With Part 2 of this series, we want to help provide resources and inspiration to up your imagery game.

5 Top Maryland Cell and Gene Therapy Companies Actively Searching for Talent

Two businesspeople shaking hands, with logos of Kite Pharma, NextCure, Arcellx, NexImmune, and MaxCyte
Published on : Published by : Steven Surdez

The BHCR cluster, in particular, includes a host of emerging and established cell and gene therapy companies, as well one of the deepest and most advanced biomanufacturing infrastructures in the U.S. While the cell and gene therapy industry still faces challenges like high manufacturing costs, high cost per dose to patients and complex supply chain issues, this sector remains very healthy and is continuing to grow rapidly in our region and globally.

Arcellx Announces Pricing of Initial Public Offering

Published on : Published by : BioBuzz Media

GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) – Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expe

Cell Therapy Companies Across Maryland are Hiring to Fill Hundreds of New Jobs

Cell Therapy Jobs
Published on : Published by : Steven Surdez

The BHCR has become a burgeoning center for cell therapy development and manufacturing. As a result, a host of cell therapy companies chose to locate themselves within the region to capitalize on its many advantages.

Arcellx Announces Kate Aiken as Chief People Officer

Published on : Published by : Andy Eckert

Arcellx, a privately held clinical-stage biopharmaceutical company, announced the addition of Kate Aiken as Chief People Officer. Kate is an accomplished human resources business leader who brings more than 20 years of cross-industry experience, building and managing high caliber HR organizations and partnering with business leaders to support the growth of industry leading companies.

Arcellx Appoints Neeraj Teotia as Chief Commercial Officer

Published on : Published by : BioBuzz Media

Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs.

Arcellx Appoints Dr. Christopher Heery as Chief Medical Officer

Published on : Published by : BioBuzz Media

Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs.

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

Published on : Published by : BioBuzz Media

Arcellx, a privately held clinical- stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022. In addition, the funding will support initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from Arcellx’s uniquely controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.

Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma

Published on : Published by : BioBuzz Media

Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma.